Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Leigh Casadaban

Concepts (137)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Chemoembolization, Therapeutic
5
2016
45
2.070
Why?
Liver Neoplasms
7
2021
504
1.970
Why?
Portasystemic Shunt, Transjugular Intrahepatic
5
2015
36
1.620
Why?
Embolization, Therapeutic
3
2022
178
1.450
Why?
Osteoarthritis, Knee
2
2022
212
1.250
Why?
Colonic Neoplasms
3
2017
210
1.050
Why?
Carcinoma, Hepatocellular
3
2016
210
0.980
Why?
End Stage Liver Disease
2
2015
61
0.870
Why?
Pain Management
2
2022
285
0.750
Why?
Positron Emission Tomography Computed Tomography
2
2021
67
0.740
Why?
Arthralgia
1
2020
46
0.690
Why?
Knee Joint
1
2022
321
0.670
Why?
Leg
1
2020
218
0.630
Why?
Ethiodized Oil
2
2016
5
0.550
Why?
Liver Transplantation
2
2014
693
0.550
Why?
Hepatic Artery
2
2015
49
0.550
Why?
Esophageal and Gastric Varices
1
2015
30
0.480
Why?
Hepatic Encephalopathy
1
2014
19
0.470
Why?
Doxorubicin
1
2016
283
0.470
Why?
Leukemia
1
2017
208
0.470
Why?
Portasystemic Shunt, Surgical
1
2014
4
0.460
Why?
Liver Function Tests
1
2014
104
0.460
Why?
Biliary Tract
1
2014
16
0.460
Why?
Gastrointestinal Hemorrhage
1
2015
100
0.460
Why?
Hypertension, Portal
1
2014
60
0.450
Why?
Emergencies
1
2015
144
0.450
Why?
Jugular Veins
1
2014
38
0.450
Why?
Adenocarcinoma
2
2017
787
0.430
Why?
Antineoplastic Combined Chemotherapy Protocols
2
2017
1356
0.390
Why?
Neovascularization, Pathologic
1
2013
280
0.380
Why?
Thrombosis
1
2013
293
0.340
Why?
Survival Rate
5
2016
1634
0.320
Why?
Fluorodeoxyglucose F18
2
2021
115
0.320
Why?
Retrospective Studies
11
2023
12504
0.310
Why?
Middle Aged
14
2021
26552
0.300
Why?
Liver
2
2018
1630
0.290
Why?
Antineoplastic Agents
3
2017
1872
0.280
Why?
Colectomy
2
2017
87
0.260
Why?
Aged, 80 and over
7
2021
6296
0.250
Why?
Treatment Outcome
8
2021
9006
0.250
Why?
Biomarkers
1
2015
3389
0.240
Why?
Angiography
3
2014
175
0.240
Why?
Chicago
2
2014
45
0.240
Why?
Neoplasm Staging
3
2017
1159
0.230
Why?
Aged
9
2021
18944
0.230
Why?
Humans
20
2023
113531
0.230
Why?
Female
16
2021
59115
0.220
Why?
Hyperaldosteronism
1
2023
8
0.220
Why?
Male
14
2018
55112
0.200
Why?
Arteries
1
2022
244
0.180
Why?
Rabbits
3
2016
713
0.170
Why?
Follow-Up Studies
3
2017
4384
0.160
Why?
Chemotherapy, Adjuvant
2
2017
332
0.150
Why?
Incidence
2
2014
2310
0.150
Why?
Pain Measurement
1
2020
440
0.150
Why?
Nitrogen Radioisotopes
1
2018
5
0.150
Why?
Ablation Techniques
1
2018
25
0.150
Why?
Propensity Score
2
2016
225
0.150
Why?
Radiography, Interventional
1
2018
105
0.140
Why?
Pain
1
2022
699
0.140
Why?
Positron-Emission Tomography
1
2018
260
0.130
Why?
In Situ Nick-End Labeling
1
2016
117
0.130
Why?
Adult
7
2021
30245
0.120
Why?
Neoplasm Grading
1
2016
241
0.120
Why?
Liver Neoplasms, Experimental
1
2015
26
0.120
Why?
Illinois
1
2015
37
0.120
Why?
Paracentesis
1
2015
6
0.120
Why?
Prosthesis Fitting
1
2015
13
0.120
Why?
Ascites
1
2015
32
0.120
Why?
Hepatic Veins
1
2015
29
0.120
Why?
Niacinamide
1
2015
63
0.120
Why?
Phenylurea Compounds
1
2015
81
0.120
Why?
Dilatation
1
2015
58
0.120
Why?
Pilot Projects
2
2018
1356
0.110
Why?
Recurrence
1
2017
925
0.110
Why?
Hepatopulmonary Syndrome
1
2014
24
0.110
Why?
Tomography, X-Ray Computed
2
2021
2269
0.110
Why?
Subtraction Technique
1
2013
24
0.110
Why?
Constriction, Pathologic
1
2014
205
0.110
Why?
Angiogenesis Inhibitors
1
2015
212
0.110
Why?
Proportional Hazards Models
1
2016
1076
0.110
Why?
Risk Factors
3
2015
8606
0.110
Why?
Vena Cava, Inferior
1
2013
55
0.110
Why?
Drug Delivery Systems
1
2016
293
0.110
Why?
Liver Cirrhosis
1
2015
226
0.110
Why?
Vena Cava Filters
1
2013
50
0.100
Why?
Guideline Adherence
1
2017
489
0.100
Why?
Device Removal
1
2013
122
0.100
Why?
Acute Disease
1
2015
885
0.100
Why?
Prosthesis Implantation
1
2013
136
0.100
Why?
Reoperation
1
2014
505
0.100
Why?
Polymerase Chain Reaction
1
2015
984
0.100
Why?
Feasibility Studies
1
2015
737
0.100
Why?
Venous Thrombosis
1
2013
142
0.100
Why?
Transcriptome
1
2017
719
0.090
Why?
Sensitivity and Specificity
1
2014
1682
0.090
Why?
Endovascular Procedures
1
2013
266
0.080
Why?
Carcinoma, Squamous Cell
1
2014
575
0.080
Why?
Practice Patterns, Physicians'
1
2017
1176
0.080
Why?
Prognosis
1
2016
3318
0.080
Why?
Reproducibility of Results
1
2014
2752
0.070
Why?
Disease Progression
1
2014
2364
0.070
Why?
Cohort Studies
1
2016
4880
0.070
Why?
Radiopharmaceuticals
2
2018
158
0.060
Why?
Aldosterone
1
2023
40
0.050
Why?
Adrenal Glands
1
2023
62
0.050
Why?
Animals
3
2016
31162
0.040
Why?
Young Adult
1
2014
10400
0.040
Why?
Hemorrhage
1
2023
599
0.040
Why?
Microwaves
1
2018
32
0.040
Why?
Organoplatinum Compounds
1
2017
37
0.030
Why?
Fluorouracil
1
2017
151
0.030
Why?
Disease Models, Animal
2
2015
3470
0.030
Why?
Injections, Intra-Arterial
1
2015
25
0.030
Why?
Equipment Failure Analysis
1
2015
131
0.030
Why?
Ultrasonography, Doppler
1
2015
103
0.030
Why?
Technetium Tc 99m Aggregated Albumin
1
2014
6
0.030
Why?
Gamma Cameras
1
2014
7
0.030
Why?
Radionuclide Imaging
1
2014
115
0.030
Why?
Yttrium Radioisotopes
1
2014
51
0.030
Why?
Neoplasm Transplantation
1
2014
227
0.030
Why?
Survival Analysis
1
2017
1203
0.030
Why?
Phlebography
1
2013
35
0.030
Why?
Hindlimb
1
2014
123
0.030
Why?
Surgical Instruments
1
2013
48
0.030
Why?
Prosthesis Design
1
2015
282
0.030
Why?
Tumor Cells, Cultured
1
2014
834
0.030
Why?
Radiography
1
2015
803
0.030
Why?
Logistic Models
1
2017
1832
0.020
Why?
Hemodynamics
1
2015
996
0.020
Why?
Practice Guidelines as Topic
1
2017
1378
0.020
Why?
Protein Kinase Inhibitors
1
2015
779
0.020
Why?
Case-Control Studies
1
2015
2993
0.020
Why?
Cell Line, Tumor
1
2014
2690
0.020
Why?
Severity of Illness Index
1
2015
2530
0.020
Why?
Prospective Studies
1
2018
6189
0.020
Why?
United States
1
2017
12137
0.010
Why?
Casadaban's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)